

## Indicator development programme

### Equality impact assessment

#### IND250 Cancer: register

1. Have any potential equality issues been identified during the development process?

No.

2. Have any population groups, treatments or settings been excluded from coverage by the indicator? Are these exclusions justified – that is, are the reasons legitimate and the exclusion proportionate?

People with non-melanotic skin cancer are not included as they are unlikely to require continuing support after treatment.

3. Does the indicator make it more difficult in practice for a specific group to access services compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group?

No.

4. Is there potential for the indicator to have an adverse impact on people with disabilities because of something that is a consequence of the disability?

No.

Completed by lead technical analyst: Eileen Taylor

Date: 03/02/2023

Approved by NICE quality assurance lead: Craig Grime

Date: 15/02/2023